314 related articles for article (PubMed ID: 36253823)
1. Tau interactome and RNA binding proteins in neurodegenerative diseases.
Kavanagh T; Halder A; Drummond E
Mol Neurodegener; 2022 Oct; 17(1):66. PubMed ID: 36253823
[TBL] [Abstract][Full Text] [Related]
2. Tau Interacting Proteins: Gaining Insight into the Roles of Tau in Health and Disease.
Stancu IC; Ferraiolo M; Terwel D; Dewachter I
Adv Exp Med Biol; 2019; 1184():145-166. PubMed ID: 32096036
[TBL] [Abstract][Full Text] [Related]
3. RNA binding proteins co-localize with small tau inclusions in tauopathy.
Maziuk BF; Apicco DJ; Cruz AL; Jiang L; Ash PEA; da Rocha EL; Zhang C; Yu WH; Leszyk J; Abisambra JF; Li H; Wolozin B
Acta Neuropathol Commun; 2018 Aug; 6(1):71. PubMed ID: 30068389
[TBL] [Abstract][Full Text] [Related]
4. Detection of Alzheimer Disease (AD)-Specific Tau Pathology in AD and NonAD Tauopathies by Immunohistochemistry With Novel Conformation-Selective Tau Antibodies.
Gibbons GS; Banks RA; Kim B; Changolkar L; Riddle DM; Leight SN; Irwin DJ; Trojanowski JQ; Lee VMY
J Neuropathol Exp Neurol; 2018 Mar; 77(3):216-228. PubMed ID: 29415231
[TBL] [Abstract][Full Text] [Related]
5. Tau-RNA complexes inhibit microtubule polymerization and drive disease-relevant conformation change.
McMillan PJ; Benbow SJ; Uhrich R; Saxton A; Baum M; Strovas T; Wheeler JM; Baker J; Liachko NF; Keene CD; Latimer CS; Kraemer BC
Brain; 2023 Aug; 146(8):3206-3220. PubMed ID: 36732296
[TBL] [Abstract][Full Text] [Related]
6. Hypersialylation is a common feature of neurofibrillary tangles and granulovacuolar degenerations in Alzheimer's disease and tauopathy brains.
Nagamine S; Yamazaki T; Makioka K; Fujita Y; Ikeda M; Takatama M; Okamoto K; Yokoo H; Ikeda Y
Neuropathology; 2016 Aug; 36(4):333-45. PubMed ID: 26685795
[TBL] [Abstract][Full Text] [Related]
7. An autoradiographic evaluation of AV-1451 Tau PET in dementia.
Lowe VJ; Curran G; Fang P; Liesinger AM; Josephs KA; Parisi JE; Kantarci K; Boeve BF; Pandey MK; Bruinsma T; Knopman DS; Jones DT; Petrucelli L; Cook CN; Graff-Radford NR; Dickson DW; Petersen RC; Jack CR; Murray ME
Acta Neuropathol Commun; 2016 Jun; 4(1):58. PubMed ID: 27296779
[TBL] [Abstract][Full Text] [Related]
8. Phosphorylated tau interactome in the human Alzheimer's disease brain.
Drummond E; Pires G; MacMurray C; Askenazi M; Nayak S; Bourdon M; Safar J; Ueberheide B; Wisniewski T
Brain; 2020 Sep; 143(9):2803-2817. PubMed ID: 32812023
[TBL] [Abstract][Full Text] [Related]
9. [Neuropathology of tauopathy].
Yoshida M
Brain Nerve; 2013 Dec; 65(12):1445-58. PubMed ID: 24323931
[TBL] [Abstract][Full Text] [Related]
10. Tauopathies and tau oligomers.
Takashima A
J Alzheimers Dis; 2013; 37(3):565-8. PubMed ID: 23948895
[TBL] [Abstract][Full Text] [Related]
11. Increased G3BP2-Tau interaction in tauopathies is a natural defense against Tau aggregation.
Wang C; Terrigno M; Li J; Distler T; Pandya NJ; Ebeling M; Tyanova S; Hoozemans JJM; Dijkstra AA; Fuchs L; Xiang S; Bonni A; Grüninger F; Jagasia R
Neuron; 2023 Sep; 111(17):2660-2674.e9. PubMed ID: 37385246
[TBL] [Abstract][Full Text] [Related]
12. AMPK is abnormally activated in tangle- and pre-tangle-bearing neurons in Alzheimer's disease and other tauopathies.
Vingtdeux V; Davies P; Dickson DW; Marambaud P
Acta Neuropathol; 2011 Mar; 121(3):337-49. PubMed ID: 20957377
[TBL] [Abstract][Full Text] [Related]
13. Tau immunophenotypes in chronic traumatic encephalopathy recapitulate those of ageing and Alzheimer's disease.
Arena JD; Smith DH; Lee EB; Gibbons GS; Irwin DJ; Robinson JL; Lee VM; Trojanowski JQ; Stewart W; Johnson VE
Brain; 2020 May; 143(5):1572-1587. PubMed ID: 32390044
[TBL] [Abstract][Full Text] [Related]
14. Structure of NFT: Biochemical Approach.
Hasegawa M
Adv Exp Med Biol; 2019; 1184():23-34. PubMed ID: 32096025
[TBL] [Abstract][Full Text] [Related]
15. Altered Proteostasis in Neurodegenerative Tauopathies.
Papanikolopoulou K; Skoulakis EMC
Adv Exp Med Biol; 2020; 1233():177-194. PubMed ID: 32274757
[TBL] [Abstract][Full Text] [Related]
16. Systemic and network functions of the microtubule-associated protein tau: Implications for tau-based therapies.
Bakota L; Ussif A; Jeserich G; Brandt R
Mol Cell Neurosci; 2017 Oct; 84():132-141. PubMed ID: 28318914
[TBL] [Abstract][Full Text] [Related]
17. Mechanisms of tau self-aggregation and neurotoxicity.
Farías G; Cornejo A; Jiménez J; Guzmán L; Maccioni RB
Curr Alzheimer Res; 2011 Sep; 8(6):608-14. PubMed ID: 21605046
[TBL] [Abstract][Full Text] [Related]
18. Unique pathological tau conformers from Alzheimer's brains transmit tau pathology in nontransgenic mice.
Guo JL; Narasimhan S; Changolkar L; He Z; Stieber A; Zhang B; Gathagan RJ; Iba M; McBride JD; Trojanowski JQ; Lee VM
J Exp Med; 2016 Nov; 213(12):2635-2654. PubMed ID: 27810929
[TBL] [Abstract][Full Text] [Related]
19. Novel drugs affecting tau behavior in the treatment of Alzheimer's disease and tauopathies.
Navarrete LP; Pérez P; Morales I; Maccioni RB
Curr Alzheimer Res; 2011 Sep; 8(6):678-85. PubMed ID: 21605038
[TBL] [Abstract][Full Text] [Related]
20. The central role of tau in Alzheimer's disease: From neurofibrillary tangle maturation to the induction of cell death.
Thal DR; Tomé SO
Brain Res Bull; 2022 Nov; 190():204-217. PubMed ID: 36244581
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
